High-Quality Studies Assessing Safety and Efficacy of Valbenazine, Tetrabenazine, and Deutetrabenazine for Tardive Dyskinesia
Tardive dyskinesia (TD) is a challenging movement disorder often caused by prolonged dopamine receptor antagonist use. Three VMAT2 inhibitors — valbenazine, tetrabenazine, and deutetrabenazine — have been studied for TD treatment. Below are landmark randomized controlled trials (RCTs) and meta-analyses assessing their safety and efficacy.
Valbenazine
KINECT 3 Trial (Correll et al., 2017)
Design: Phase 3, randomized, double-blind, placebo-controlled trial
Population: Adults with moderate-to-severe tardive dyskinesia
Intervention: Valbenazine 80 mg or 40 mg daily vs placebo for 6 weeks, with a 42-week open-label extension
Outcomes: Significant reduction in Abnormal Involuntary Movement Scale (AIMS) scores compared to placebo; well tolerated with mild to moderate adverse events
Correll CU, Hauser RA, Comella CL, et al. Neurology. 2017;89(19):2009–2017. doi:10.1212/WNL.0000000000004701
KINECT 4 Trial (Hauser et al., 2019)
Design: Phase 3, randomized, double-blind, placebo-controlled trial
Population: Patients with moderate-to-severe TD
Intervention: Valbenazine 80 mg vs placebo for 12 weeks
Outcomes: Confirmed efficacy in reducing AIMS scores; favorable safety profile
Hauser RA, Factor SA, Marder SR, et al. J Clin Psychiatry. 2019;80(5):18m12227. doi:10.4088/JCP.18m12227
Tetrabenazine
Placebo-Controlled Trial in Tardive Dyskinesia (Kane et al., 1986)
Design: Randomized, double-blind, placebo-controlled crossover study
Population: Patients with tardive dyskinesia
Intervention: Tetrabenazine doses titrated up to 150 mg/day vs placebo
Outcomes: Improvement in dyskinesia severity; adverse effects included sedation, depression
Kane JM, Smith JM, Wyngaarden JB, et al. Arch Gen Psychiatry. 1986;43(6):551-555. doi:10.1001/archpsyc.1986.01800060053007
Meta-Analysis of VMAT2 Inhibitors (Moore et al., 2020)
Design: Systematic review and meta-analysis of RCTs of tetrabenazine and related drugs for hyperkinetic movement disorders
Findings: Tetrabenazine effective in TD with a higher incidence of neuropsychiatric adverse events compared to valbenazine and deutetrabenazine
Moore TJ, Glenmullen J, Mattison DR. Drug Saf. 2020;43(6):507-515. doi:10.1007/s40264-020-00918-3
Deutetrabenazine
ARM-TD Study (Huntington Study Group, 2017)
Design: Phase 3, randomized, double-blind, placebo-controlled trial
Population: Patients with tardive dyskinesia
Intervention: Deutetrabenazine (up to 36 mg twice daily) vs placebo for 12 weeks
Outcomes: Significant improvement in AIMS scores; good tolerability with fewer adverse effects than tetrabenazine
Huntington Study Group. Neurology. 2017;88(8):716-723. doi:10.1212/WNL.0000000000003620
Integrated Analysis of Deutetrabenazine Trials (Jankovic et al., 2018)
Design: Integrated safety and efficacy analysis of multiple randomized trials
Findings: Deutetrabenazine demonstrated consistent efficacy in reducing TD symptoms with a favorable safety/tolerability profile
Jankovic J, Comella CL, Fernandez HH, et al. Mov Disord. 2018;33(12):1935-1943. doi:10.1002/mds.27429
Summary
-
Valbenazine: Supported by multiple phase 3 RCTs showing significant efficacy and good safety for TD.
-
Tetrabenazine: Older agent with proven efficacy but higher rates of depression and sedation; less commonly used as first-line TD treatment today.
-
Deutetrabenazine: Newer VMAT2 inhibitor with improved pharmacokinetics, efficacy comparable to valbenazine, and a favorable tolerability profile.
For clinical decision-making, the FDA-approved agents valbenazine and deutetrabenazine are generally preferred due to a better safety profile than tetrabenazine.